Chagas Disease Management Market Business Strategies, Product Sales and Growth Rate, Assessment to 2028

Precision Business Insights published a research report on “Chagas Disease Management Market: By Treatment Type (Antiparasitic treatment, Symptomatic treatment), By Drug Type (Benznidazole, Nifurtimox), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies) - Global/Region/Country Forecast to 2028”.

Chagas disease is a kinetoplastid protozoan parasite transmitted by Trypanosoma cruzi that is largely spread by huge, blood-sucking reduviid insects known as "kissing bugs" in 21 Latin American nations. In addition, the disease can be spread through various methods such as blood transfusion, organ transplantation, congenital, and oral transmissions. Owing to movement of people from Latin America to other nations, Chagas disease has recently spread to developed economies such as Europe and North America. According to a report released in the National Center for Biotechnology Information (NCBI), Chagas disease afflicted 4.2 percent of Latin Americans living in European countries in 2015. Only benznidazole has been approved by the FDA for the treatment of Chagas disease.

View detailed report description here https://precisionbusinessinsights.com/market-reports/chagas-disease-management-market/

The number of people suffering with chagas illness is rising over the world. The main causes of this predicament are filthy environments and a growing global population. The chagas disease treatment market is growing as a result of these causes. Aside from that, the market is projected to see new companies enter and innovative technologies for the treatment of Chagas disease develop. Several competitors in the chagas disease therapy market have been boosting their research efforts in recent years. The development of novel therapeutic options for chagas disease is the primary motivation for this move. Furthermore, a number of vendors have received authorisation for the launch of new items. The market for chagas disease therapy is growing as a result of these causes. During the forecast period of 2019 to 2027, however, some factors are expected to hamper the expansion of the chagas disease treatment market. The need for increased knowledge about chagas disease therapy, the current market's limited number of approved medicines, and supply chain challenges with chagas disease drugs are some of the important concerns that market players will need to focus on in the next years.

Based on type, the chagas disease treatment market is categorized into chronic chagas disease and acute chagas disease. In terms of treatment, the chagas disease treatment market is categorized into symptomatic treatment and antiparasitic treatment. In terms of drugs, the chagas disease treatment market is divided into nifurtimox and benznidazole. On the basis of route of administration, the chagas disease treatment market is fragmented into oral as well as injectable. Based on end users, the chagas disease treatment market is classified into homecare settings, hospitals, specialty clinics, and others. In terms of distribution channel, the chagas disease treatment market is divided into retail pharmacies, hospital pharmacies, and others.

Owing to the increased research and development expenditures, an increase in the number of patients, and a favourable reimbursement environment in this region, North America dominates the chagas disease treatment market. For the forecast period, Asia-Pacific is expected to have the fastest growth rate and the highest CAGR. This is due to expanding government spending on healthcare infrastructure, growing government attempts to raise awareness, as well as rising personal disposable income.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=15817

Some of the major key players in the Chagas Disease Management Market are AstraZeneca (U.K) Bayer AG (Germany) Daiichi Sankyo Company Ltd (Japan) Eisai Co Ltd (Japan) GlaxoSmithKline Plc. (U.K) Grupo Praxis Pharmaceutical SA (Spain) KaloBios Pharmaceuticals, Inc. (U.S.) Kancera AB (Sweden) Novartis AG (Switzerland) Laboratorio Elea S.A.C.I.F. y A (Argentina) Oblita Therapeutics BVBA (Belgium) Sanofi (France)

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.